Anne E. Dixon, M.D.
Director, Clinical Research

Vermont Lung Center
792 College Parkway
Medical Office Building, Suite # 105
Colchester, VT  05446

Voice:  (802) 847-6981
Fax: (802) 847-4187

Email: Anne.Dixon@vtmednet.org

• B.A. (1987) 2:1 Natural Sciences; Cambridge University, England.
• B.M., B.Ch (1990) Oxford University, England.
• Internship (1990) Medical House Officer; Milton Keynes Hospital, England.
• Internship (1991) Surgical House Officer; John Radcliffe, Oxford, England.
• Internship (1993-1994) Internal Medicine; Johns Hopkins Hospital, Baltimore, MD.
• Residency (1994-1996) Internal Medicine; Johns Hopkins Hospital, Baltimore, MD.
• Fellowship (1996-1999) Pulmonary and Critical Care Medicine; University of Washington, Seattle, WA.
• Acting Instructor (1999-2000) Pulmonary and Critical Care Medicine, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA.
• Assistant Professor (2001-present), Pulmonary and Critical Care Medicine, University of Vermont and Fletcher Allen Health Care
• Director Clinical Research (2001-Present), Vermont Lung Center, College of Medicine University of Vermont.

Dr. Dixon is interested in clinical trials & researching new therapies for asthma and COPD.  She has a particular interest in understanding how sinus disease and rhinitis effect the control of asthma.

• Adherence of adoptively transferred alloreactive Th1 cells in lung: partial dependence on LFA-1 and ICAM-1. (Am J Physiol Lung Cell Mol Physiol 2000, 279: L583-91)
   
   
• Chemokine expression in Th1 cell mediated lung inflammation: prominence of IFN-g inducible chemokines. (Am J Physiol Lung Cell Mol Physiol 2000, 279: L592-7)
   
   
• Neutralization of TNF-a may delay but does not prevent lung injury induced by alloreactive Th1 cells. (Transplantation 2000, 70:39-43)
   
   
• Alloreactive Th1 cells localize in lung and induce acute lung injury. (Chest 1999, 116:36s-37s)